Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
11%(1 trials)

Phase Distribution

Ph phase_2
1
8%
Ph phase_3
1
8%
Ph phase_4
2
15%
Ph phase_1
2
15%
Ph not_applicable
6
46%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
1(8.3%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
6(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)
Other(2)

Detailed Status

Completed9
Not yet recruiting1
unknown1
Withdrawn1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (16.7%)
Phase 21 (8.3%)
Phase 31 (8.3%)
Phase 42 (16.7%)
N/A6 (50.0%)

Trials by Status

completed969%
not_yet_recruiting18%
unknown18%
withdrawn18%
suspended18%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13